Table of Contents List of Tables List of Figures Introduction Global Markets Direct Report Coverage Mitogen Activated Protein Kinase Kinase Kinase 5 (Apoptosis Signal Regulating Kinase 1 or MAPK/ERK Kinase Kinase 5 or MAP3K5 or EC 2.7.11.25) - Overview Mitogen Activated Protein Kinase Kinase Kinase 5 (Apoptosis Signal Regulating Kinase 1 or MAPK/ERK Kinase Kinase 5 or MAP3K5 or EC 2.7.11.25) - Therapeutics Development Products under Development by Stage of Development Products under Development by Therapy Area Products under Development by Indication Products under Development by Companies Products under Development by Universities/Institutes Mitogen Activated Protein Kinase Kinase Kinase 5 (Apoptosis Signal Regulating Kinase 1 or MAPK/ERK Kinase Kinase 5 or MAP3K5 or EC 2.7.11.25) - Therapeutics Assessment Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Mitogen Activated Protein Kinase Kinase Kinase 5 (Apoptosis Signal Regulating Kinase 1 or MAPK/ERK Kinase Kinase 5 or MAP3K5 or EC 2.7.11.25) - Companies Involved in Therapeutics Development Angion Biomedica Corp Chipscreen Biosciences Ltd CJ HealthCare Corp Gilead Sciences Inc Kyowa Hakko Kirin Co Ltd Takeda Pharmaceutical Co Ltd Mitogen Activated Protein Kinase Kinase Kinase 5 (Apoptosis Signal Regulating Kinase 1 or MAPK/ERK Kinase Kinase 5 or MAP3K5 or EC 2.7.11.25) - Drug Profiles ANG-4102 - Drug Profile Product Description Mechanism Of Action R&D Progress CS-410 - Drug Profile Product Description Mechanism Of Action R&D Progress GS-444217 - Drug Profile Product Description Mechanism Of Action R&D Progress GS-459679 - Drug Profile Product Description Mechanism Of Action R&D Progress selonsertib - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecule to Inhibit ASK-1 for Chronic Pain - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecule to Inhibit ASK1 for Liver Disease - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecule to Inhibit ASK1 for Thrombosis - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules to Inhibit Apoptosis Signal-Regulating Kinase 1 for Unspecified Indication - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules to Inhibit ASK1 for Amyotropic Lateral Sclerosis - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules to Inhibit ASK1 for Rheumatoid Arthritis, Myocardial Infarctions and Neurodegenerative Diseases - Drug Profile Product Description Mechanism Of Action R&D Progress Mitogen Activated Protein Kinase Kinase Kinase 5 (Apoptosis Signal Regulating Kinase 1 or MAPK/ERK Kinase Kinase 5 or MAP3K5 or EC 2.7.11.25) - Dormant Products Mitogen Activated Protein Kinase Kinase Kinase 5 (Apoptosis Signal Regulating Kinase 1 or MAPK/ERK Kinase Kinase 5 or MAP3K5 or EC 2.7.11.25) - Discontinued Products Mitogen Activated Protein Kinase Kinase Kinase 5 (Apoptosis Signal Regulating Kinase 1 or MAPK/ERK Kinase Kinase 5 or MAP3K5 or EC 2.7.11.25) - Product Development Milestones Featured News & Press Releases Apr 20, 2017: Gilead to Present Additional Clinical Data on Selonsertib at The International Liver Congress 2017 Nov 14, 2016: Phase 2 Data for Selonsertib in Nonalcoholic Steatohepatitis Presented at The Liver Meeting 2016 Oct 20, 2016: Gilead Announces Top-Line Phase 2 Results for GS-4997 (Selonsertib) in Nonalcoholic Steatohepatitis, Pulmonary Arterial Hypertension and Diabetic Kidney Disease Apr 16, 2016: Gilead Presents New Data on GS-4997 at The International Liver Congress 2016 Appendix Methodology Coverage Secondary Research Primary Research Expert Panel Validation Contact Us Disclaimer

List of Tables Number of Products under Development by Stage of Development, H2 2017 Number of Products under Development by Therapy Areas, H2 2017 Number of Products under Development by Indication, H2 2017 Number of Products under Development by Companies, H2 2017 Products under Development by Companies, H2 2017 Products under Development by Companies, H2 2017 (Contd..1), H2 2017 Number of Products under Investigation by Universities/Institutes, H2 2017 Products under Investigation by Universities/Institutes, H2 2017 Number of Products by Stage and Mechanism of Actions, H2 2017 Number of Products by Stage and Route of Administration, H2 2017 Number of Products by Stage and Molecule Type, H2 2017 Pipeline by Angion Biomedica Corp, H2 2017 Pipeline by Chipscreen Biosciences Ltd, H2 2017 Pipeline by CJ HealthCare Corp, H2 2017 Pipeline by Gilead Sciences Inc, H2 2017 Pipeline by Kyowa Hakko Kirin Co Ltd, H2 2017 Pipeline by Takeda Pharmaceutical Co Ltd, H2 2017 Dormant Projects, H2 2017 Discontinued Products, H2 2017 List of Figures Number of Products under Development by Stage of Development, H2 2017 Number of Products under Development by Therapy Areas, H2 2017 Number of Products under Development by Top 10 Indications, H2 2017 Number of Products by Stage and Mechanism of Actions, H2 2017 Number of Products by Stage and Route of Administration, H2 2017 Number of Products by Stage and Molecule Type, H2 2017

Angion Biomedica Corp Chipscreen Biosciences Ltd CJ HealthCare Corp Gilead Sciences Inc Kyowa Hakko Kirin Co Ltd Takeda Pharmaceutical Co Ltd